Adenylate Cyclase 9 Expression Level is Associated with Hormone Receptor-positive Breast Cancer and Predicts Patient Prognosis

Overview

Journal Nagoya J Med Sci

Date 2025 Jan 9

PMID 39780930

Authors

Kayoko Sugino

Masahiro Shibata

Yayoi Adachi

Ikumi Soeda

Takahiro Ichikawa

Takahiro Inaishi

Emi Kanaya

Mitsuro Kanda

Masamichi Hayashi

Norikazu Masuda

Affiliations

Soon will be listed here.

Abstract

Adenylate cyclase family members have recently received attention as novel therapeutic targets. However, the significance of adenylate cyclase 9 (ADCY9) in breast cancer has not been elucidated. Here, we evaluated expression in breast cancer (BC) cell lines, and polymerase chain reaction array analysis was performed to determine the correlations between expression levels and 84 tumor-associated genes. The association of messenger RNA (mRNA) expression levels in clinical breast cancer specimens with patients' clinicopathological factors and prognosis was evaluated. The database of cancer cell line showed that estrogen receptor-positive and progesterone receptor-positive cells expressed higher mRNA levels. expression showed positive correlations with several oncogenes, such as and in the polymerase chain reaction array analysis. We defined the ratio of mRNA expression levels in breast cancer and adjacent noncancerous tissues as the "C/N ratio". Among 149 patients with BC, estrogen receptor-positive and progesterone receptor-positive patients exhibited higher C/N ratios than estrogen receptor-negative and progesterone receptor-negative patients, respectively. Patients in the lowest C/N ratio quartile experienced shorter prognosis periods. The C/N ratio of was found as an independent prognostic factor for disease-free survival. Thus, expression is high in hormone receptor-positive breast cancer, and its low expression indicates a poor prognosis in patients with breast cancer.

References

Li H, Liu Y, Liu J, Sun Y, Wu J, Xiong Z . Assessment of ADCY9 polymorphisms and colorectal cancer risk in the Chinese Han population. J Gene Med. 2020; 23(2):e3298. DOI: 10.1002/jgm.3298. View

Beaber E, Malone K, Tang M, Barlow W, Porter P, Daling J . Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):755-64. PMC: 4032363. DOI: 10.1158/1055-9965.EPI-13-0944. View

Shibata M, Kanda M, Shimizu D, Tanaka H, Umeda S, Hayashi M . Expression of regulatory factor X1 can predict the prognosis of breast cancer. Oncol Lett. 2017; 13(6):4334-4340. PMC: 5453005. DOI: 10.3892/ol.2017.6005. View

Tang Y, Wang T, Zhang A, Zhu J, Zhou T, Zhou Y . ADCY9 functions as a novel cancer suppressor gene in lung adenocarcinoma. J Thorac Dis. 2023; 15(3):1018-1035. PMC: 10089850. DOI: 10.21037/jtd-22-1027. View

Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y . p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol. 1997; 107(6):684-91. DOI: 10.1093/ajcp/107.6.684. View

Gyorffy B, Lanczky A, Eklund A, Denkert C, Budczies J, Li Q . An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2009; 123(3):725-31. DOI: 10.1007/s10549-009-0674-9. View

Kiba T, Inamoto T, Nishimura T, Ueno M, Yanagihara K, Teramukai S . The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery. BMC Cancer. 2008; 8:323. PMC: 2585098. DOI: 10.1186/1471-2407-8-323. View

Jia S, Li L, Xie L, Zhang W, Zhu T, Qian B . Transcriptome Based Estrogen Related Genes Biomarkers for Diagnosis and Prognosis in Non-small Cell Lung Cancer. Front Genet. 2021; 12:666396. PMC: 8081391. DOI: 10.3389/fgene.2021.666396. View

Inaishi T, Shibata M, Ichikawa T, Kanda M, Hayashi M, Soeda I . Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer. Oncol Rep. 2021; 47(1). DOI: 10.3892/or.2021.8220. View

10.

Lumachi F, Ermani M, Marino F, Di Cristofaro L, Tombolan V, Brunello A . Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer. Anticancer Res. 2008; 28(1B):491-3. View

11.

Zarzynska J . Two faces of TGF-beta1 in breast cancer. Mediators Inflamm. 2014; 2014:141747. PMC: 4033515. DOI: 10.1155/2014/141747. View

12.

Ichikawa T, Shibata M, Inaishi T, Soeda I, Kanda M, Hayashi M . Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer. Curr Oncol. 2021; 28(5):4080-4092. PMC: 8535095. DOI: 10.3390/curroncol28050346. View

13.

Subik K, Lee J, Baxter L, Strzepek T, Costello D, Crowley P . The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010; 4:35-41. PMC: 2914277. View

14.

Zhang H, Kong Q, Wang J, Jiang Y, Hua H . Complex roles of cAMP-PKA-CREB signaling in cancer. Exp Hematol Oncol. 2020; 9(1):32. PMC: 7684908. DOI: 10.1186/s40164-020-00191-1. View

15.

Finn R, Dering J, Conklin D, Kalous O, Cohen D, Desai A . PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009; 11(5):R77. PMC: 2790859. DOI: 10.1186/bcr2419. View

16.

Guo R, Liu T, Shasaltaneh M, Wang X, Imani S, Wen Q . Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy. Front Oncol. 2022; 12:829212. PMC: 9271773. DOI: 10.3389/fonc.2022.829212. View

17.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

18.

Yi H, Wang K, Jin J, Jin H, Yang L, Zou Y . Elevated Adenylyl Cyclase 9 Expression Is a Potential Prognostic Biomarker for Patients with Colon Cancer. Med Sci Monit. 2018; 24:19-25. PMC: 5759510. DOI: 10.12659/msm.906002. View

19.

Li W, Sang M, Hao X, Jia L, Wang Y, Shan B . Gene expression and DNA methylation analyses suggest that immune process-related ADCY6 is a prognostic factor of luminal-like breast cancer. J Cell Biochem. 2019; 121(7):3537-3546. DOI: 10.1002/jcb.29633. View

20.

Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F . p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer. 1996; 74(2):208-15. PMC: 2074571. DOI: 10.1038/bjc.1996.339. View